scholarly journals Advances in Prognostic Methylation Biomarkers for Prostate Cancer

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2993 ◽  
Author(s):  
Dilys Lam ◽  
Susan Clark ◽  
Clare Stirzaker ◽  
Ruth Pidsley
Keyword(s):  
Prostate Cancer ◽  
Dna Methylation ◽  
Specific Antigen ◽  
Treatment Strategies ◽  
Cancer Prognosis ◽  
Comprehensive Overview ◽  
Current State ◽  
Genome Wide ◽  
Indolent Disease ◽  
Prostate Cancer Prognosis

There is a major clinical need for accurate biomarkers for prostate cancer prognosis, to better inform treatment strategies and disease monitoring. Current clinically recognised prognostic factors, including prostate-specific antigen (PSA) levels, lack sensitivity and specificity in distinguishing aggressive from indolent disease, particularly in patients with localised intermediate grade prostate cancer. There has therefore been a major focus on identifying molecular biomarkers that can add prognostic value to existing markers, including investigation of DNA methylation, which has a known role in tumorigenesis. In this review, we will provide a comprehensive overview of the current state of DNA methylation biomarker studies in prostate cancer prognosis, and highlight the advances that have been made in this field. We cover the numerous studies into well-established candidate genes, and explore the technological transition that has enabled hypothesis-free genome-wide studies and the subsequent discovery of novel prognostic genes.

scholarly journals Advances in Prognostic Methylation Biomarkers for Prostate Cancer

2020 ◽  
Author(s):  
Dilys Lam ◽  
Susan Clark ◽  
Clare Stirzaker ◽  
Ruth Pidsley
Keyword(s):  
Prostate Cancer ◽  
Dna Methylation ◽  
Specific Antigen ◽  
Treatment Strategies ◽  
Cancer Prognosis ◽  
Comprehensive Overview ◽  
Current State ◽  
Genome Wide ◽  
Indolent Disease ◽  
Prostate Cancer Prognosis

There is a major clinical need for accurate biomarkers for prostate cancer prognosis, to better inform treatment strategies and disease monitoring. Current clinically recognised prognostic factors, including prostate-specific antigen (PSA) levels, lack sensitivity and specificity in distinguishing aggressive from indolent disease, particularly in patients with localised intermediate grade prostate cancer. There has therefore been a major focus on identifying molecular biomarkers that can add prognostic value to existing markers, including investigation of DNA methylation, which has a known role in tumorigenesis. In this review, we will provide a comprehensive overview of the current state of DNA methylation biomarker studies in prostate cancer prognosis, and highlight the advances that have been made in this field. We cover the numerous studies into well-established candidate genes, and explore the technological transition that has enabled hypothesis-free genome-wide studies and the subsequent discovery of novel prognostic genes.

Discovery and Validation of 3 Novel DNA Methylation Markers of Prostate Cancer Prognosis

2007 ◽  
Vol 177 (5) ◽  
pp. 1753-1758 ◽  
Author(s):  
Susan Cottrell ◽  
Klaus Jung ◽  
Glen Kristiansen ◽  
Elke Eltze ◽  
Axel Semjonow ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dna Methylation ◽  
Cancer Prognosis ◽  
Prostate Cancer Prognosis

Value of Prostate Specific Antigen Density and Percent Free Prostate Specific Antigen for Prostate Cancer Prognosis

2012 ◽  
Vol 188 (6) ◽  
pp. 2165-2170 ◽  
Author(s):  
Jonas Busch ◽  
Kristin Hamborg ◽  
Hellmuth-Alexander Meyer ◽  
John Buckendahl ◽  
Ahmed Magheli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Cancer Prognosis ◽  
Prostate Specific Antigen Density ◽  
Prostate Cancer Prognosis

scholarly journals Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer

1998 ◽  
Vol 116 (5) ◽  
pp. 1798-1802
Author(s):  
Francisco Paulo da Fonseca ◽  
Ademar Lopes ◽  
Walter Antonio Melarato Jr. ◽  
Wilson Bachega Jr. ◽  
Osvaldo Junior Batista Marques ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Rate ◽  
Prostate Specific Antigen ◽  
Advanced Prostate Cancer ◽  
Specific Antigen ◽  
Cancer Prognosis ◽  
Final Examination ◽  
Global Survival ◽  
Prostate Cancer Prognosis

OBJECTIVE: To evaluate the survival rate of patients with advanced prostate cancer in a univariate form, according to the preoperative and first postoperative determination of PSA levels. MATERIALS AND METHODS: From February 1987 to June 1995, 92 patients were submitted to maximum blockage androgen (subcapsular and antiandrogen orchiectomy), independent of clinical symptons shown upon admission to the Cancer Hospital. The antiandrogens (ciproterone acetate and flutamide) were administered until the patient present progression of the disease. RESULTS: The age of patients varied from 44 to 89, with a median of 70 years old. In the 6th, 36th and 60th months the global survival rate was 80%, 38% and 20%, respectively. The preoperative PSA ranged from 2 to 4017 ng/ml, with a median of 98 ng/ml (98% had PSA greater than or equal to 10 ng/ml). The first postoperative PSA ranged from 1 to 3840 ng/ml, with a median of 20 ng/ml. There was a tendency towards a better survival rate only in patients with initial PSA from 2 to 99 ng/ml (p=0.06745). The survival rate of patients at 36 months after the initial total blockage androgen, with first PSA level from 1 to 4, 5 to 49 and over 49 ng/ml was 72%, 48% and 8%, respectively (p=0.00004). In the final examination, 34 (37%) patients were considered stable and 58 (63%) had disease progression. CONCLUSION: The PSA determination performed on the 30th postoperative day is important in the evaluation of advanced prostate cancer prognosis.

scholarly journals Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Andreas Dimakakos ◽  
Athanasios Armakolas ◽  
Michael Koutsilieris
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Therapeutic Response ◽  
Specific Antigen ◽  
Cancer Prognosis ◽  
Paper Briefly ◽  
Future Directions ◽  
Prognosis And Prediction ◽  
Prostate Cancer Prognosis

Prostate-specific antigen (PSA) is the main diagnostic tool when it comes to prostate cancer but it possesses serious limitations. Therefore, there is an urgent need for more sensitive and specific biomarkers for prostate cancer prognosis and patient follow-up. Recent advances led to the discovery of many novel diagnostic/prognostic techniques and provided us with many worthwhile candidates. This paper briefly reviews the most promising biomarkers with respect to their implementation in screening, early detection, diagnostic confirmation, prognosis, and prediction of therapeutic response or monitoring disease and recurrence; and their use as possible therapeutic targets. This review also examines the possible future directions in the field of prostate cancer marker research.

Prostate-Specific Antigen Kinetics under Androgen Deprivation Therapy and Prostate Cancer Prognosis

2013 ◽  
Vol 91 (1) ◽  
pp. 38-48 ◽  
Author(s):  
Li-min Zhang ◽  
Hao-wen Jiang ◽  
Shi-jun Tong ◽  
Hui-qing Zhu ◽  
Jun Liu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Androgen Deprivation Therapy ◽  
Specific Antigen ◽  
Androgen Deprivation ◽  
Cancer Prognosis ◽  
Prostate Cancer Prognosis
Sign in / Sign up

Export Citation Format

Share Document